Expertise in
5
conditions

Abrahim A. Mamgani-Al

Amsterdam UMC
Amsterdam, NH, NL 
Expertise in
5
conditions
Amsterdam UMC
Amsterdam, NH, NL 

Overview

Abrahim Mamgani-Al practices practicing medicine in Amsterdam, Netherlands.

Mr. Mamgani-Al is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Dry Mouth, Throat Cancer, Laryngeal Cancer, and Laryngectomy.

He is actively involved in clinical research, co-authoring 120 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Amsterdam UMC
Amsterdam, NH, Netherlands
Other Locations
Rotterdam, ZH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma
Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma
Enrollment Status: Unknown
Publish Date: November 07, 2023
Intervention Type: Radiation, Drug
Study Drug: Olaparib
Study Phase: Phase 1
Mapping of Sentinel Lymph Node Drainage Using SPECT to Tailor Highly-Selective Elective Nodal Irradiation in Node-Negative Neck of Patients With Head and Neck Cancer (SUSPECT)
Mapping of Sentinel Lymph Node Drainage Using SPECT to Tailor Highly-Selective Elective Nodal Irradiation in Node-Negative Neck of Patients With Head and Neck Cancer (SUSPECT)
Enrollment Status: Completed
Publish Date: June 27, 2019
Intervention Type: Radiation
Study Phase: Not Applicable
View 1 Less Clinical Trial

120 Total Publications

The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials.
The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 17, 2026

Frequently Asked Questions about Abrahim A. Mamgani-Al

Is Abrahim A. Mamgani-Al a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Abrahim A. Mamgani-Al is classified as an Distinguished expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Abrahim A. Mamgani-Al participate in research or clinical trials?

Yes. Abrahim A. Mamgani-Al has published 120 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Abrahim A. Mamgani-Al's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mamgani-Al's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile